23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
Veradigm ends exploration of strategic alternatives without deal
Veradigm (MDRX) announced that its board of directors completed its previously announced review of strategic alternatives. “Throughout the
Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review
Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “
Genetic test maker 23andMe eyes strategic alternatives, including a sale
CEO Anne Wojcicki last spring proposed buying out the company and taking it private. Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said ...
23andMe announces exploration of strategic alternatives
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss
NGVT to Evaluate Strategic Alternatives for Industrial Specialties
Ingevity Corporation NGVT recently announced plans to explore strategic alternatives for its Performance Chemicals Industrial Specialties product line, including a potential divestiture of a portion of the company’s North Charleston site.
23andMe says it's exploring alternatives, including a sale
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, licensing of assets,
23andMe Special Committee Announces Exploration of Strategic Alternatives
The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special Committee has engaged Moelis & Company LLC as its financial advisor and Goodwin Procter LLP as its legal advisor.
Crain's Chicago Business2d
Veradigm fails to find a buyer, moves to operational review
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Yahoo Finance6d
Novaturas will assess strategic alternatives
The analysis of strategic alternatives will include an assessment of various possible scenarios, including but not limited to raising additional capital or attracting a strategic investor ...